Likewise, @edyong209 is on ithttps://www.theatlantic.com/health/archive/2020/05/coronavirus-strains-transmissible/611239/ …
-
-
Show this thread
-
A few key tips for reporting on mutation preprints...
Show this thread -
Whoops—bad threading. You can read the tips starting here:https://twitter.com/carlzimmer/status/1258097769723637761 …
Show this thread
End of conversation
New conversation -
-
-
When someone publishes a potentially momentous paper, especially not-peer reviewed, and does not respond to a ‘request for comment’ [especially to a widely read/respected science journalist as
@carlzimmer], that is immediately suspicious. I wonder what is really going on? -
Money is going on lol
End of conversation
New conversation -
-
-
Thanks much for this -- I was one of those people this preprint was making more anxious...
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
P.13 _ It has been shown that for cellular entry of SARS-CoV-2, ACE2 and TMPRSS2 are indispensable D614G mutation discussion https://www.biorxiv.org/content/10.1101/2020.05.04.075911v1.full.pdf … camostat mesilate inhibits the protease TMPRSS2 https://neurosciencenews.com/tmprss2-coronavirus-treatment-15873/ …pic.twitter.com/JmZrfsbs4O
-
human recombinant soluble angiotensin-converting enzyme 2 (hrs ACE2) https://med.ubc.ca/news/ubc-led-study-finds-trial-drug-can-significantly-block-early-stages-of-covid-19-in-engineered-human-tissues/ … https://ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147863 … https://cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00739.pdf … https://eurekalert.org/multimedia/pub/228393.php … https://apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf____________ … -
End of conversation
New conversation -
-
-
that's reason #26 why you need to stop it FAST
#COVIDThanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.